Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study crawled time : 14:20 save search
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
Published: 2023-08-02 (Crawled : 14:20) - biospace.com/
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.12%
H: 0.12%
C: -0.14%
partnership health therapeutics study
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Published: 2023-08-01 (Crawled : 14:20) - biospace.com/
CVAC | News | $2.44 -5.06% -5.33% 670K
|
Health Technology
|
| O: -0.86%
H: 0.65%
C: -1.2%
covid-19 vaccine mrna collaboration study
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
Published: 2023-06-22 (Crawled : 14:20) - biospace.com/
SEEL | $0.338 1.81% -3.11% 280K
|
Health Technology
|
| O: 3.77%
H: 10.91%
C: 2.73%
sls-002 therapeutics study
First of its Kind Joint Study Demonstrates Copper’s Effectiveness at Killing Bacteria and Viruses on Public Transit
Published: 2023-05-18 (Crawled : 14:20) - globenewswire.com
TECK | $47.72 1.1% -1.38% 2.9M
|
Non-Energy Minerals
|
| O: -1.88%
H: 0.85%
C: 0.33%
bacteria study
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
Published: 2023-05-03 (Crawled : 14:20) - biospace.com/
KPTI | $1.28 -7.25% -9.09% 1.3M
|
Health Technology
|
| O: 0.56%
H: 4.86%
C: 1.67%
presentation international study
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
Published: 2022-03-10 (Crawled : 14:20) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: -2.13%
H: 13.04%
C: 6.61%
biotech presentation meeting results study
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
Published: 2022-05-19 (Crawled : 14:20) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.12%
bbi-02 biotech study
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
Published: 2023-04-20 (Crawled : 14:20) - biospace.com/
DARE | $0.2951 4.39% 5.45% 980K
|
Health Technology
|
| O: 0.0%
H: 0.99%
C: -0.99%
bioscience study
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
Published: 2023-04-17 (Crawled : 14:20) - prnewswire.com
ELEV | $4.01 -3.14% -2.73% 300K
|
Professional, Scientific, and T...
|
| O: -2.05%
H: 4.71%
C: 1.57%
eo-3021 preclinical study
Study Finds Healthcare Providers Looking to Outsource Revenue Cycle Management Processes
Published: 2023-04-06 (Crawled : 14:20) - prnewswire.com
SYF | $40.8 2.82% -1.45% 4.2M
|
Finance
|
| O: 0.21%
H: 1.79%
C: 0.21%
management study
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
Published: 2023-02-23 (Crawled : 14:20) - globenewswire.com
ATOS | $1.42 5.19% 4.26% 2.3M
|
Health Technology
|
| O: 0.0%
H: 6.94%
C: 2.85%
women breast cancer study her2
Synopsys Study Underscores Need for Comprehensive SBOM as Best Defense in Software Supply Chain Security
Published: 2023-02-22 (Crawled : 14:20) - prnewswire.com
SNPS A | $519.71 -1.49% -1.54% 1M
|
Technology Services
|
| O: 0.59%
H: 1.3%
C: 0.17%
defense security software study
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
Published: 2023-02-14 (Crawled : 14:20) - globenewswire.com
IRME | $0.969 -15.74% 108.33% 980
|
|
| O: -0.47%
H: 0.0%
C: -8.61%
device agreement study
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Published: 2023-02-06 (Crawled : 14:20) - neurosense.investorroom.com
NRSN | News | $1.52 -5.0% -5.96% 270K
|
|
| O: -4.91%
H: 5.81%
C: 1.94%
fda canada als trial potential study phase 2b
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Published: 2023-02-06 (Crawled : 14:20) - ir.pulmatrix.com
PULM | $1.96 -6.22% -7.18% 31K
|
Health Technology
|
| O: 1.82%
H: 3.44%
C: 1.42%
pur1900 treatment study phase 2b
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Published: 2023-01-24 (Crawled : 14:20) - globenewswire.com
SAVA | $21.19 -0.38% -0.42% 910K
|
Health Technology
|
| O: -6.97%
H: 1.97%
C: -13.16%
sciences disease alzheimer’s positive results study phase 2
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
Published: 2023-01-23 (Crawled : 14:20) - biospace.com/
EOLS | $11.56 -0.69% -0.69% 340K
|
Health Technology
|
| O: 0.36%
H: 3.61%
C: -0.54%
jeuveau study
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
BICX | $1.47 -2.0% 201.91% 4
|
Health Care and Social Assistan...
|
| O: 3.25%
H: 0.0%
C: 0.0%
bicx104 treatment opioid trial study
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
CYBN | News | $0.3699 -1.47% -2.68% 1.6M
|
n/a
|
| O: 2.89%
H: 6.23%
C: -6.25%
flow results study train
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: -0.22%
treatment trial therapeutics study
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.